Trials / Not Yet Recruiting
Not Yet RecruitingNCT06641674
EGFR Mutation Targeting Molecular Probe for PET Imaging
Development and Clinical Translation of EGFR Mutation Targeting PET Probe
- Status
- Not Yet Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 20 (estimated)
- Sponsor
- Peking University Cancer Hospital & Institute · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
In this project, investigators plan to develop a F-18 labeled molecular probe in order to detect the EGFR mutation tumor lessions in patients to identify patients benefiting fromTKIs treatment, and evaluate its efficacy in detecting EGFR Del 19 mutant lung cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 18F-LF13 | 18F-LF13 PET/CT: after intravenous injection of 1.85 - 3.7 MBq/kg body weight of quality-controlled 18F-LF13, a Siemens Biograph PET/CT scan will be applied within 0.5 h, and the scan range will be from the top of the head to 1/3 of the upper thigh, 2 h to 4 h delayed scanning can be added if necessary. |
Timeline
- Start date
- 2024-11-15
- Primary completion
- 2025-12-31
- Completion
- 2026-12-31
- First posted
- 2024-10-15
- Last updated
- 2024-10-15
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06641674. Inclusion in this directory is not an endorsement.